HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)

Vaccines

Maggiorino Barbero¹  Antonio Perino²  Ankica Lukic³  Antonio Frega³  Rosa De Vincenzo⁴  Jacopo Di Giuseppe⁵  Giovanni Delli Carpini⁵  Luca Giannella⁵  Andrea Ciavattini⁵  Maria Papiccio⁵  Francesco Sopracordevole⁶  Murat Gultekin⁷ 

[1] Department of Obstetrics and Gynecology, Asti Community Hospital, 14100 Asti, Italy;Department of Sciences for Health Promotion and Mother-Child Care “G. D’Alessandro”, Polyclinic University Hospital, 90127 Palermo, Italy;Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, S. Andrea Hospital, 00185 Rome, Italy;Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, 00168 Rome, Italy;Gynecologic Section, Department of Odontostomatologic and Specialized Clinical Sciences, Università Politecnica delle Marche, 60121 Ancona, Italy;Gynecological Oncology Unit, Centro di Riferimento Oncologico-National Cancer Institute, 33081 Aviano, Italy;Gynecology and Obstetrics, Division of Gynecologic Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey;

关键词: human papillomavirus;    cervical cancer;    cervical intraepithelial neoplasia;    HPV vaccine;    primary prevention;   

DOI  :  10.3390/vaccines8030354

来源: DOAJ

【 摘 要 】

Human papillomavirus (HPV) related cervical cancer represents an issue of public health priority. The World Health Organization recommended the introduction of HPV vaccination in all national public programs. In Europe, vaccines against HPV have been available since 2006. In Italy, vaccination is recommended and has been freely offered to all young girls aged 11 years since 2008. Three prophylactic HPV vaccines are available against high- and low-risk genotypes. The quadrivalent vaccine contains protein antigens for HPV 6, 11, 16, and 18. The bivalent vaccine includes antigens for HPV 16 and 18. The nonavalent vaccine was introduced in 2014, and it targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58. Clinical trials demonstrated the effectiveness of the three vaccines in healthy young women. Likewise, all vaccines showed an excellent safety profile. The bivalent vaccine provides two doses in subjects aged between 9 and 14 years and three doses in subjects over 14 years of age. The quadrivalent vaccine provides two doses in individuals from 9 to 13 years and three doses in individuals aged 14 years and over. The nonavalent vaccine schedule provides two doses in individuals from 9 to 14 years of age and three doses in individuals aged 15 years and over at the time of the first administration. Preliminary results suggest that the HPV vaccine is effective in the prevention of cervical squamous intraepithelial lesions even after local treatment. Given these outcomes, in general, it is imperative to expand the vaccinated target population. Some interventions to improve the HPV vaccine’s uptake include patient reminders, physicians-focused interventions, school-based vaccinations programs, and social marketing strategies. The Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV) is committed to supporting vaccination programs for children and adolescents with a catch-up program for young adults. The SICPCV also helps clinical and information initiatives in developing countries to decrease the incidence of cervico-vaginal and vulvar pathology.

【 授权许可】

Unknown